ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Lumata Health Expands Leadership Bench with New Chief Technology Officer and Chief Growth Officer

Seasoned Leadership Joins to Support Growth and R&D and Meet Demand for Continuous Care Solution in Retinal Disease

Lumata Health, the company focused on ending preventable blindness with continuous ophthalmic care for people facing chronic eye disease, today announced two new executive hires to propel the company into its next phase of expansion to meet the ophthalmic sector’s demand for its retinal disease treatment adherence solution.

Annu Singh has been named Chief Technology Officer, leading the company's strategy and execution to build scalable, data-enabled, AI-assisted eye care. With more than 25 years of experience building platforms and products for Fortune 500 and Global 5000 companies, Annu brings expertise in developing adaptive architectures and launching innovative, patient-centered solutions. Annu has built and scaled platforms from the ground up, serving over 15 million users across health-tech and ed-tech sectors. He has played a pivotal role in multiple companies through acquisition exits totaling $600M and a $1B+ IPO.

Nastran Andersen has joined as Chief Growth Officer, bringing nearly 30 years of experience driving revenue growth in the healthcare industry to the company. She has a proven track record of leading high-performing teams across sales, marketing, and client success, fostering collaboration to achieve business expansion. Nastran has worked with Fortune 10 and Fortune 500 companies, private equity-backed firms, and small- to mid-sized organizations across provider organizations, health plans, post-acute, and emerging areas such as new care models and age tech.

“This year has been a period of significant expansion as we continue to meet the demand for our proven continuous care solution for people living with vision-threatening eye disease,” said Landon Grace, CEO of Lumata Health. “The exceptional talent we’ve brought on positions us to accelerate adoption among physicians, pharmaceutical partners, and patients. As we broaden our footprint and invest in new technologies, we remain committed to advancing the standard of care for chronic eye-disease management, strengthening visit and treatment adherence to ensure patients receive the care they need when they need it.”

Lumata Health offers a continuous care model to patients with retinal diseases, powered by its data-driven predictive analytics platform that anticipates patient needs beyond the clinic and proactively delivers education and support at critical points in the treatment journey. Between patients’ visits to the office, the company’s trained ophthalmic technicians reinforce the retina specialist’s treatment plan, identify and resolve barriers to care, and coordinate logistics that often disrupt treatment.

About Lumata Health

Lumata Health is focused on eliminating preventable blindness with continuous ophthalmic care for people facing vision-threatening chronic eye disease. The company partners with eye-care practices and pharmaceutical companies to provide personalized, between-visit support that helps patients adhere to their medication treatment plans and proactively participate in preserving their vision. The company is backed by LRVHealth, McKesson Ventures, and Cencora Ventures, with participation from other venture firms, including Cortado Ventures. For more information, visit www.lumatahealth.com.

“This year has been a period of significant expansion as we continue to meet the demand for our proven continuous care solution for people living with vision-threatening eye disease,” said Landon Grace, CEO of Lumata Health.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.